<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985916</url>
  </required_header>
  <id_info>
    <org_study_id>ET-01-LCL-210</org_study_id>
    <nct_id>NCT04985916</nct_id>
  </id_info>
  <brief_title>ET-01 in Subjects With Lateral Canthal Lines, LCL-210</brief_title>
  <official_title>Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eirion Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eirion Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A,&#xD;
      topical, in lateral canthal lines (LCL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This product is being tested for its ability to reduce lateral canthal lines (LCL), also&#xD;
      known as Crow's Feet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>vehicle controlled, parallel group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA (Investigators Global Assessment)</measure>
    <time_frame>Week 4</time_frame>
    <description>Investigators Global Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA (Investigators Global Assessment)</measure>
    <time_frame>Week 2, 4, 8,12, and 18</time_frame>
    <description>Investigators Global Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSA (Subject Self-Assessment)</measure>
    <time_frame>Week 2, 4, 8,12, and 18</time_frame>
    <description>Subject Self-Assessment. Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Lateral Canthal Lines, LCL</condition>
  <condition>Crow's Feet</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle, topical liniment, administered once at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET-01, Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of botulinum toxin, Type A, topical liniment, administered once at baseline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ET-01, Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of botulinum toxin, Type A, topical liniment, administered once at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>topical liniment without investigational product</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>ET-01 Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin, Type A</intervention_name>
    <description>ET-01 topical liniment</description>
    <arm_group_label>ET-01, Dose 1</arm_group_label>
    <arm_group_label>ET-01, Dose 2</arm_group_label>
    <other_name>ET-01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults 25 - 65 years of age&#xD;
&#xD;
          -  mild or less Crow's Feet wrinkles (IGA 0-2) &quot;at rest&quot;&#xD;
&#xD;
          -  moderate to severe Crow's Feet (IGA 3-4) &quot;on contraction&quot;&#xD;
&#xD;
          -  adequate vision to assess facial wrinkles in a mirror&#xD;
&#xD;
          -  willingness to refrain from products affecting skin remodeling&#xD;
&#xD;
          -  female subjects must be not pregnant and non-lactating&#xD;
&#xD;
          -  subjects should be in good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of adverse reactions to any prior botulinum toxin treatments&#xD;
&#xD;
          -  history of vaccination or non-response to any prior botulinum toxin treatments&#xD;
&#xD;
          -  botulinum toxin treatment in the prior 6 months&#xD;
&#xD;
          -  present or history of neuromuscular disease, eyelid ptosis, muscle weakness,&#xD;
             paralysis, or &quot;dry eye&quot;&#xD;
&#xD;
          -  history of peri-ocular surgery, brow lift or related procedures&#xD;
&#xD;
          -  procedures affecting the lateral canthal region in the prior 12 months&#xD;
&#xD;
          -  application of topical prescription medication to the treatment area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus PJ Theobald, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Eirion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical and Cosmetic Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baumann Cosmetic &amp; Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Southeast, LLC</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lupo Center for Aesthetic &amp; General Dermatology</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KGL Skin Study Center</name>
      <address>
        <city>Newtown Square</city>
        <state>Pennsylvania</state>
        <zip>19073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

